TITLE

MUJERES FELICES POR SER SALUDABLES: THE ASSOCIATION BETWEEN ATTENDANCE AND OUTCOME IN A DIETARY/BREAST HEALTH RANDOMIZED CLINICAL TRIAL FOR LATINAS

AUTHOR(S)
Fitzgibbon, Marian L; Martinovich, Zoran; Gapstur, Susan M.
PUB. DATE
September 2005
SOURCE
American Journal of Health Studies;2005, Vol. 20 Issue 3/4, p194
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Method. Two hundred fifty-six 20-40 year-old Latinas were randomly assigned to the intervention (n=127) or control group (n=129). Data were collected at a baseline and eight-months after randomization. Results. Compared to women who attended 0-2 sessions, those who attended at least three of the 16 sessions reported lower dietary fat (p<.001) and improved BSE proficiency (p<.001). However, there were no differences in fiber intake at eight months. Women who attended at least three sessions were more likely to be lower in acculturation. Conclusions. The optimal length for health-risk reduction interventions is unknown. Our results suggest that, while participation is associated with improved outcomes, fewer sessions than traditionally offered in most behavioral interventions may be sufficient to effect initial behavior change.
ACCESSION #
23652082

 

Related Articles

  • HEALTH RESEARCH: Nat'l Cancer Institute Has $5.4M to Expand Modeling Network.  // Community Health Funding Week;7/17/2009, p13 

    The article offers information on the Cancer Intervention & Surveillance Modeling Network (CISNET) program of the U.S. National Cancer Institute (NCI). The goal of CISNET is to use simulation and other modeling techniques to understand the impact of cancer control interventions on national...

  • CANCER. PARK, ALICE // Time International (South Pacific Edition);2/14/2011, Vol. 177 Issue 6, p18 

    The article discusses a large British clinical trial of breast-cancer risk in menopausal women who use combination estrogen-and-progestin pills and estrogen-only pills for hormone therapy.

  • CANCER. PARK, ALICE // Time;2/14/2011, Vol. 177 Issue 6, p18 

    The article discusses a large British clinical trial of breast-cancer risk in menopausal women who use combination estrogen-and-progestin pills and estrogen-only pills for hormone therapy.

  • Selecting targets for cancer prevention: where do we go from here? Szabo, Eva // Nature Reviews Cancer;Nov2006, Vol. 6 Issue 11, p867 

    Given the lack of progress in curing metastatic epithelial cancers, there is intense interest in, and a sound scientific rationale for, pursuing strategies to prevent cancer. However, although several clinical trials have shown efficacy in cancer prevention, few have resulted in changes to...

  • Innate Immunity Pathways and Breast Cancer Risk in African American and European-American Women in the Women’s Circle of Health Study (WCHS). Gong, Zhihong; Quan, Lei; Yao, Song; Zirpoli, Gary; Bandera, Elisa V.; Roberts, Michelle; Coignet, Jean-Gabriel; Cabasag, Citadel; Sucheston, Lara; Hwang, Helena; Ciupak, Gregory; Davis, Warren; Pawlish, Karen; Jandorf, Lina; Bovbjerg, Dana H.; Ambrosone, Christine B.; Hong, Chi-Chen // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    African American (AA) women are more likely than European American (EA) women to be diagnosed with early, aggressive breast cancer. Possible differences in innate immune pathways (e.g., inflammatory responses) have received little attention as potential mechanisms underlying this disparity. We...

  • Pipeline.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p10 

    The article offers news briefs related to clinical trials in the U.S. The Finnish Breast Cancer Group states that women are prone to risk of breast cancer who uses capecitabine as part of their chemotherapy regimen. The preliminary results of the Phase III study with E7389 on patients who have...

  • The effectiveness of a graphical presentation in addition to a frequency format in the context of familial breast cancer risk communication: a multicenter controlled trial. Henneman, Lidewij; Oosterwijk, Jan C.; van Asperen, Christi J.; Menko, Fred H.; Ockhuysen-Vermey, Caroline F.; Kostense, Piet J.; Claassen, Liesbeth; Timmermans, Daniëlle RM. // BMC Medical Informatics & Decision Making;2013, Vol. 13 Issue 1, p1 

    Background: Inadequate understanding of risk among counselees is a common problem in familial cancer clinics. It has been suggested that graphical displays can help counselees understand cancer risks and subsequent decision-making. We evaluated the effects of a graphical presentation in addition...

  • Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Rae, J. M.; Sikora, M. J.; Henry, N. L.; Li, L.; Kim, S.; Oesterreich, S; Skaar, T. C.; Nguyen, A. T.; Desta, Z.; Storniolo, A. M.; Flockhart, D. A.; Hayes, D. F.; Stearns, V. // Pharmacogenomics Journal;2009, Vol. 9 Issue 4, p258 

    The selective estrogen receptor modulator tamoxifen is routinely used for treatment and prevention of estrogen-receptor-positive breast cancer. Studies of tamoxifen adherence suggest that over half of patients discontinue treatment before the recommended 5 years. We hypothesized that...

  • New Clinical Trial to Investigate Treatment Options for Breast Cancer. Sweeney, Rosemarie; Neff, Matthew // American Family Physician;7/1/2001, Vol. 64 Issue 1, p21 

    Deals with the Phase III clinical trial that will evaluate the effectiveness of exemestane in inhibiting recurrent tumor growth in high-risk breast cancer patients. Characteristics of the study population;; Side effects of exemestane.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics